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Abstract  
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease resulting 
from the dysregulation of various immunological pathways. There has been 
major progress in recent years in the understanding of the pathogenesis of SLE, 
which has led to an emergence of a new class of drugs designed to target specific 
components of the disease process.  
Evidence from a number of open-label, uncontrolled studies has supported the 
use of Rituximab (an anti-CD20 monoclonal antibody) in SLE for more than one 
decade. However, these promising results are in clear contrast with the poor 
results of the completed Efficacy and Safety of Rituximab in Patients with Severe 
SLE (EXPLORER) and Efficacy and Safety of Rituximab in Subjects with ISN/RPS 
Class III or IV Lupus Nephritis (LUNAR) randomized controlled trials (RCTs). In 
contrast to EXPLORER and LUNAR results, controlled trials for Belimumab (a 
fully humanised monoclonal antibody against B lymphocyte stimulator) showed 
positive results and subsequently, Belimumab was the first drug approved for 
the treatment of SLE patients. This has paved the way for the development of 
further biological agents, potentially revolutionising the treatment of SLE. 
In this article, the potential benefits of novel biological agents are explored, 
obstacles to the development of a treatment target in SLE are identified, and 
possible strategies to achieve this goal are discussed. 
 
Introduction 
 
Systemic lupus erythematosus (SLE, lupus) is a chronic autoimmune 
inflammatory disease, mainly affecting young women. It is often considered 
paradigmatic of systemic autoimmune diseases. SLE has a wide range of systemic 
effects with multi-organ involvement. Although the exact cause of SLE is 
unknown, its pathogenesis is based on the production of autoantibodies and pro-
inflammatory cytokines that results in multisystem inflammation and presents in 
a highly variable relapsing and remitting disease course. The clinical spectrum of 
SLE varies, ranging from general malaise, arthralgia and fever to more severe 
manifestations including renal and CNS disease (1).  
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The current treatment of SLE includes hydroxychloroquine, an anti-malarial 
agent, corticosteroids, and cytotoxic immunosuppressive agents (2). 
Corticosteroids, given orally or intravenously, are effective for almost all SLE 
related manifestations. However, the short and long-term adverse effects 
including those related to the metabolic (such as hyperglycemia and 
hyperlipemia), musculoskeletal, endocrine, cardiovascular, and the central 
nervous system, limit their usage (3). Among others, Thamer et al. demonstrated 
that a dose of as low as 6 mg prednisone per day greatly increases the risk of 
corticosteroid-induced organ damage (4). More recently, Ruiz-Arruza et al 
showed that prednisone doses >7.5 mg/day are associated with damage accrual 
(5) and thus, a steroid sparing therapeutic approach is mandatory.  
Other immunosuppressive agents such as cyclophosphamide, azathioprine, 
methotrexate and mycophenolate mofetil were shown to be effective in the 
treatment of SLE but these agents also have significant short and long-term 
adverse effects (6). Moreover, although the above treatment modalities are quite 
effective they are not specific for SLE and the control of disease activity with 
those agents remains suboptimal. Thus, in spite of treatment, SLE patients have 
active lupus related flares in substantial fractions of their life (6). Therefore, 
there is an unmet need for alternative nontoxic, effective and more lupus-specific 
therapeutic approaches. 
  
Pathogenesis  
 
Although the precise aetiology of SLE remains unclear, it is well understood that 
deregulation of both the innate and the adaptive immune system results in 
ineffective clearance of apoptotic nuclear fragments. These fragments are then 
processed and presented by antigen presenting cells, such as B cells, to auto-
reactive T cells, which in turn triggers auto-B cells into self-antibody production. 
Cytokines released at the same time are thought to enhance this effect and 
further induce auto T cell activation (7).  
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The role of the B cell in SLE pathogenesis has been repeatedly demonstrated by 
murine studies, most notably by one study using a knockout gene mutation to 
prevent lupus mice developing B cells. This resulted in no evidence of 
autoantibody formation or clinical manifestation of lupus and thus validates the 
key role of B cell auto-reactivity in the disease course (8). Furthermore, these 
mice had a significantly reduced number of activated T cells, which indicates the 
crucial interaction between B and T cells in SLE pathogenesis (9).  
 
With the plethora of evidence that places B cells at the heart of the disease 
process underlying SLE, it is by no means surprising that in recent years a great 
deal of research has been focused on the development of novel B cell specific 
biologics for the treatment of SLE. In this article we will review the current 
biologic agents available and up to date research on newer drugs that have all 
been specifically designed to target the most intricate pathways that are central 
to SLE pathogenesis (figure 1).  
 
B cell targeted therapies  
 
B cells can be selectively targeted for depletion either via direct killing by 
monoclonal antibodies against B cell surface molecules CD19, CD20 (Rituximab, 
Ocrelizumab) and CD22 (Epratuzumab) or by attrition due to inhibition of B cell 
survival factors BLyS (Belimumab) and APRIL (Atacicept) (10). Here we discuss 
the key cell surface markers implicated in the pathogenesis of SLE that are the 
targets of these novel biologic drugs.  
 
Anti-CD20 
Rituximab  
Rituximab is perhaps the most well known biologic agent and is widely used in 
the treatment of rheumatoid arthritis and ANCA-associated vasculitis. Rituximab 
is an anti-CD20 human-murine monoclonal chimeric antibody that causes 
selective short-term depletion of matured B cells (7). Two recent randomised 
controlled trials (RCTs) have evaluated the use of rituximab in patients with SLE.  
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The controlled EXPLORER (The Exploratory Phase II/III SLE Evaluation of 
Rituximab) trial included 257 patients with moderate-severe SLE and extra-
renal manifestations over a 1-year period (11). Patients were randomised to the 
addition of rituximab or placebo to the standard therapy of immunosuppressive 
agents and corticosteroids. Anti-CD20 therapy significantly improved serological 
markers including reduced autoantibodies (p < 0.06), improved complement 
levels (p = 0.0045, p = 0.0029) and B cell depletion. However, there was in fact 
no statistically significant reduction in clinical activity between placebo (28.4%) 
and treatment (29.6%) arms in achieving a clinical response (p = 0.975).  
Although the results of this study suggest the use of monoclonal antibodies such 
as Rituximab may not be effective therapies for moderate-severe SLE, it is 
important to note that the follow-up period was short and as the SLE activity 
score assessment was thoroughly scrutinised, any mild disease flare was seen as 
a failure of treatment. Furthermore, the Rituximab arm showed minimal disease 
activity and no further flares in 14.5% more patients compared to the placebo 
arm (p = 0.027), which suggests that rituximab may provide benefit to those with 
severe lupus (12). 
 
The second RCT was the Lupus Nephritis Assessment With Rituximab (LUNAR) 
trial, which evaluated the efficacy of rituximab compared to placebo in 
combination with Standard of Care therapy in 144 patients with proliferative 
lupus nephritis (13). Treatment with Rituximab was associated with the 
successful depletion of B cells in 99% of patients and ameliorating serological 
markers of active lupus. Despite this improvement, again there was no 
significant difference in overall renal response rates or clinical efficacy at 1 
year between placebo (45.8%) and treatment arms (56.9%) of the trial (p = 
0.18). 
However, before concluding that Rituximab is not a good therapy for SLE, a 
careful evaluation of the design of the EXPLORER and LUNAR trials is 
mandatory. With regard to disease severity, a high percentage of patients 
included are likely to have had mild to moderate SLE (especially in the 
EXPLORER trial) with no history of poor response to standard therapies. This 
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observation, in itself, may explain why Rituximab was not superior to the other 
drugs in these predominantly non-complicated patients. Considering 
concomitant therapies, the high doses of corticosteroids permitted in both arms 
of these trials could lead to significant differences not being apparent in a short-
term evaluation. In addition, the possible synergistic effect of Rituximab in 
combination with immunosuppressive agents (cyclophosphamide or 
mycophenolate), suggested by some authors to have significant advantages in 
complicated, refractory SLE cases (14), was not evaluated in these RCTs. 
Regarding ethnic factors, the two RCTs included a different sub set of patients 
(mainly american patients, predominantly from the US and Canada, but also from 
Mexico, Brazil, and Argentina) when compared to the majority of patients from 
uncontrolled studies were (European). This consideration about ethnicity is 
important because some studies have suggested a variable therapeutic response 
to the main immunosuppressive agents in different ethnic groups (15).  
Finally, the demonstration of the superiority of Rituximab over current first-line 
therapies in SLE (corticosteroids, cyclophosphamide, and mycophenolate) does 
not correlate with the use of Rituximab in clinical practice, i.e. its overwhelming 
use in patients with SLE refractory to these therapies. Furthermore, the fact that 
Rituximab was not shown to be superior to other therapies does not necessarily 
signify that it is inferior. 
 
Ocrelizumab  
A further anti-CD20 monoclonal antibody, Ocrelizumab, was studied in two 
doses (400mg and 1g) in The Study to Evaluate Ocrelizumab in Patients With 
Nephritis Due to SLE (BELONG) trial that included 381 patients with severe 
lupus nephritis. However the trial was suspended early due to the detection of a 
severe infection-related safety signal in the treatment arm. Nonetheless the 
report from the BELONG trial did show a trend to a better response in the 
ocrelizumab 400mg (62%) and 1g (64%) treatment arm compared with placebo 
(51%); thus suggesting there is potential for the use of this drug in SLE. Despite 
the results, ocrelizumab has not been studied further (16).  
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Anti-CD22 
Epratuzumab  
Epratuzumab is a humanised monoclonal antibody to the CD22 surface receptor 
present on mature B cells. Like CD20, CD22 play a key role in controlling B cell 
responses to antigens. Epratuzumab reduces the number of auto-B cells via 
antibody dependent cellular cytotoxic mechanisms (17).  
 
Two studies reported clinical improvement, compared to placebo, in 14 
(ALLIVIATE 1) and 90 (ALLIVIATE 2) patients with active lupus disease 
following epratuzumab treatment (12). Epratuzumab was well tolerated without 
severe adverse events. The 12-week phase IIb, multicentre, randomised 
controlled study was conducted with 227 patients and the primary endpoint was 
the week 12 responder rate measured using a novel composite endpoint, the 
British Isles Lupus Assessment Group (BILAG)-based Combined Lupus 
Assessment (BICLA). There was a significantly greater reduction in BILAG 
scores 48 weeks post treatment with increasing doses of treatment. The 
treatment also enabled steroid sparing, suggesting a significant clinical benefit. 
Overall treatment with epratuzumab 2400 mg was well tolerated in patients 
with moderately to severely active SLE, and associated with improvements in 
disease activity (18).  
 
These encouraging results have lead to the development of two phase III studies 
(EMBODY 1 and 2), that aim to confirm the clinical efficacy of Epratuzumab in 
the treatment of patients with moderate to severe SLE, in addition to continuing 
standard of care treatments (19).  
 
B Lymphocyte Stimulator (BLyS) and A Proliferation Inducing Ligand 
(APRIL) targeted therapy  
 
BLyS and APRIL are two key B cell stimulatory cytokines. BLyS is a 285 amino 
acid transmembrane protein belonging to the tumour necrosis factor ligand 
superfamily and is present on the surface of macrophages, monocytes, dendritic 
cells and activated T cells (20). BLyS is a growth factor required for B-cell 
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maturation, activation and survival and acts by binding to thee receptors (BCMR 
– B cell maturation antigen, TACI – transmembrane activator and calcium 
modulator and cyclosporin interactor and BR3 and BR3 – BLyS/BAFF receptor 
3). APRIL has been shown to bind to BCMA and TACI on B cells. Studies have 
shown that the concentration of these cytokines correlates with disease severity 
and serological markers, such as anti-dsDNA antibody levels, suggesting they 
play a key role in the pathogenesis of SLE (21). This is supported by evidence 
from murine studies whereby lupus-prone mice engineered to overexpress BLyS 
go on to develop severe SLE (7). Similarly, knockout-BLyS mice have reduced 
mortality and approximately 80% reduced disease severity at 1 year (22).  
 
Belimumab  
Belimumab is an IgG1 monoclonal antibody that antagonises BLyS and inhibiting 
its activity (20). The efficacy and safety of this new drug have been tested in two 
pioneering multicentre, double blind randomized controlled trials, BLISS-52 (23) 
and BLISS-76 (24), which included 1684 lupus patients with mild to moderate 
disease activity (without lupus nephritis/CNS). These studies demonstrated a 
significant improvement in disease outcome with 10mg/kg of Belimumab as 
compared to placebo. The beneficial effects of Belimumab were measured using 
the SLE responder index (SRI), which combines the SLE disease activity index 
(SLEDAI), the British Island lupus assessment group (BILAG) and the physicians’ 
global assessment (PGA) (24,25).  
 
The BLISS-52 group showed SRI rates 1-year post treatment as 58% (p=0.0006), 
51% (p=0.00129), and 44% in the Belimumab 10mg/Kg, 2mg/Kg and placebo 
groups respectively. This demonstrates a significant clinical benefit with 
increased dose of Belimumab. In addition, Belimumab treatment also reduced 
SLE-related flares, normalised C3 levels and reduced steroid usage (23). This is 
particularly useful for the patient in terms of reduced steroid associated side 
effects.  
 
The BLISS-76 trial further supported the significant clinical benefits of 
Belimumab shown by the BLISS-52 trial, with the results demonstrating reduced 
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active disease, relapse rates, time to onset of relapse and steroid requirement 
compared to placebo, in a dose-dependent manner (24). Furthermore, they 
showed that Belimumab significantly reduced the risk of severe relapses over 
the trial period compared to placebo, with 26.5% of the placebo arm reporting a 
severe flare compared to only 18.5% in the low dose treatment arm (p=0.023). 
Overall the results from these studies provide robust evidence for the use of 
Belimumab in the treatment of SLE. It was based on the results of the BLISS trials 
that in 2011 Belimumab was approved by the FDA and EMA and has become the 
first drug approved for SLE for over 50 years (25).  
 
Since the approval there has been an on going seven-year follow up of lupus 
patients assessing the tolerability and efficacy of Belimumab in addition to 
standard of care therapies. The results remain positive with a maintained 
reduction in corticosteroid use and low rates of adverse effects (26). The authors 
also described a 70% decline from baseline in autoantibodies to dsDNA at 7 
years after treatment.   
 
Overall these results suggest that targeting BLyS with the novel biologic 
Belimumab can provide significant clinical benefit to SLE patients and is well 
tolerated long-term (27). However, it is important to note that Belimumab 
displays only marginal effectiveness in mild to moderate manifestations of the 
disease, a considerable proportion of patients did not respond to the treatment 
(65% response rate over 7 years) and Belimumab was less effective among 
African-American patients (28). However some of these failings could be 
explained by the fact that only half of lupus patients show permanent BLyS 
elevation (29).  
 
Blisibimod and Tabalumab  
Owing the success of Belimumab and its recent FDA approval, there has since 
been two further anti-BLyS drugs introduced, Blisibimod and Tabalumab, which 
are currently being assessed in a phase III RCT to evaluate their benefit in the 
treatment of SLE (30,31).  
 
 10 
Blisibimod is a fusion between the Fc portion of IgG and a peptide that 
selectively binds to BLyS. Results of the phase II trial (PEARL-SC) were positive, 
with high dose Blisibimod (200mg once weekly) producing significantly higher 
responder rates compared to placebo in patients with ≥7 (25%) or ≥8 (25%) 
point reduction in SLEDAI (p = 0.003, p = 0.001 respectively). Furthermore, 
patients with baseline severe SLE (SLEDAI ≥ 10 and under corticosteroid 
treatment) showed an even greater improvement with 41.7% responder rate 
achieving either ≥7 or ≥8 SLEDAI point decrease in the high dose Blisibimod 
group compared to placebo (p = 0.002, p < 0.001 respectively). These results 
were associated with a significant decrease in anti-ds DNA (p < 0.001) and 
increase in C3 (p < 0.01) and C4 (p < 0.001) in the Blisibimod arm compared to 
placebo (32). Due to positive early results of this trial, the efficacy and 
tolerability of Blisibimod is currently being assessed in patients with highly 
active and refractory SLE, the results of which are eagerly anticipated.  
Tabalumab is a monoclonal antibody directed against soluble and membrane 
bound BLyS. The efficacy and safety of Tabalumab in SLE patients was recently 
assessed in two phase III RCTs (33,34). However, the Eli Lilly and Company 
announced that further development of Tabalumab would be discontinued due 
to insufficient efficacy (34). It has been reported that the decision was not based 
on safety concerns. In the ILLUMINATE 1 study, Tabalumab did not achieve the 
primary endpoint, at either dose studied, of statistically significant improvement 
on SRI-5 (SLE Responder Index-5, a measurement of lupus disease activity and 
response), compared to standard of care therapy. In ILLUMINATE 2, the higher 
dose of Tabalumab met this endpoint, the first time a lupus study has achieved 
this efficacy measure as a primary endpoint in a Phase 3 trial. Collectively, the 
data from these studies did not meet the company’s expectations for efficacy in 
the context of existing treatments. The overall safety profile showed a similar 
frequency of adverse events in patients treated with either Tabalumab or normal 
standard of care.  
 
Atacicept  
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Atacicept is a recombinant fusion protein containing the Fc portion of IgG and 
the TACI receptor that binds both BLyS and APRIL, thus inhibiting both these B 
cell stimulating factor (35). In a phase I RCT, which included 49 patients with 
mild to moderate lupus, Atacicept was shown to have beneficial therapeutic 
effects, inducing a 45-60% attenuation in mature B cells and dose dependent 
decreases in autoantibody levels, compared to placebo (36). However, despite 
these early positive results, the phase I/II RCT of Atacicept in patients with lupus 
nephritis was terminated prematurely due to safety concerns (37).  
 
T cell targeted therapies  
 
T cells are activated by two independent signals, one from the engagement of the 
MHC complex with the T cell receptor and the other via the interaction of co-
stimulatory molecules, such as CD28 and CTLA-4 (expressed on T cells) and 
CD80/86, expressed on antigen presenting cells (38). It is thought that inhibiting 
T cell activation could be effective in the treatment of SLE.  
 
Abatacept  
Abatacept is a fusion protein of cytotoxic T lymphocyte antigen 4 (CTLA-4) and 
the Fc portion of human IgG1. CTLA-4 binds efficiently to CD80/86, thus 
preventing T cell co-stimulation via the CD28 pathway. Abatacept was proven to 
be effective in the treatment of murine lupus (39) and in patients with 
rheumatoid arthritis (40). However, the results from clinical trials of patients 
with SLE were disappointing and Abatacept treatment was deemed to be not 
effective compared to placebo. The primary endpoint was the proportion of 
patients who flared following tapering of their glucocorticoids and, after 1 year, 
around 80% of patients had flared in both groups. However Abatacept did show 
evidence of biologic activity and was well tolerated in patients with active class 
III or IV lupus nephritis (41). Interestingly Wofsy et al. (42) looked at the choice 
of parameters for abatacept trials and deemed that if alternative parameters 
were chosen then the trial is likely to have been a success. They suggest there is 
strong rationale to conduct further studies of abatacept in the treatment of lupus 
nephritis.  
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Six patients suffering from overlapping rheumatoid arthritis and SLE (Rhupus 
syndrome) with active arthritis refractory to methotrexate treatment were 
shown to benefit significantly from Abatacept treatment according to Clinical 
Disease Activity Index (CDAI), Health Assessment Questionnaire-Disability Index 
(HAQ-DI) and EULAR scores (43). Median CDAI scores attenuated by 16.55 (p = 
0.028) 3 months post treatment suggesting significant clinical benefit of 
Abatacept in these patients. SLEDAI scores were also shown to significantly 
decrease up to 6 months post treatment with improvements seen in both 
articular and non-articular manifestations, which included rash and fever. In 
correlation with this, anti-DNA antibody decreased by median 10.7 (p = 0.043) 6 
months post treatment suggesting Abatacept may have its benefits by affecting 
autoantibody production in SLE. Currently Abatacept is not approved for lupus 
treatment, although some clinicians use it as an off label agent.  
 
Cytokine blockade targeted therapies  
 
Tocilizumab (anti-IL-6 receptor mAb) 
IL-6 is a pro-inflammatory cytokine with high levels were found in the sera of 
patients with active lupus (44). Tocilizumab is a humanised monoclonal 
antibody against the IL-6 receptor, thus preventing IL-6 activation. The drug is 
yet to be assessed by controlled trials but a small phase I trial that included 16 
patients suggested that Tocilizumab is safe and beneficial in SLE (17). Further 
trials are required to fully assess the therapeutic role of Tocilizumab in the 
treatment of lupus.  
 
Sirukumab (anti-IL-6 mAb) 
Like Tocilizumab, sirukumab is also a humanised, anti-IL-6 monoclonal antibody 
that binds to IL-6 and inhibits its biological activity (45). A recent phase II trial 
using Sirukumab on lupus nephritis patients showed that patients with active 
lupus nephritis did not result in a median improvement in proteinuria and 
almost half of those who treated with Sirukumab developed a serious adverse 
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event (46). Thus owing to these negative results, the trials for Sirukumab in 
lupus nephritis have been discontinued.  
 
Anakinra (human recombinant IL-1 receptor antagonist (IL-1 Ra)) 
IL-1 is another pro-inflammatory cytokine implicated in the pathogenesis of SLE. 
Anakinra is a recombinant IL-1 Ra that blocks IL-1 activity and thus has potential 
in the treatment of SLE (47). It is currently used in the treatment of severe 
rheumatoid arthritis. Although recent uncontrolled trials have demonstrated 
beneficial effects of Anakinra (48), further controlled trials are required to assess 
its efficacy and safety in the treatment of SLE.  
 
Sifalimumab (anti-interferon alpha (IFN-α)) 
One of the most exciting advances in the field of cytokine-targeted therapy in SLE 
is the development of Sifalimumab, a human IgG1 monoclonal antibody that 
targets IFN-α, an inflammatory cytokine thought to play a key role in the 
development of SLE (17). The results from a recent phase IIb trial showed that 
the study met its primary endpoint of percentage of subjects that responded by 
the SLE Responder Index (SRI-4) at Day 365, and clinical benefits in organ-
specific outcomes measures (joints, skin) was also observed (49).  
 
The study evaluated three doses of Sifalimumab (200mg, 600mg, 1200mg) 
against placebo when added to standard of care therapy in patients with 
moderate to severe lupus despite standard of care therapy. As well as the 
meeting its primary endpoint, the study also achieved improvements in skin 
rashes as measured by CLASI (Cutaneous Lupus Erythematosus Disease Area 
and Severity Index) and improvement in fatigue.  
 
Although still in their early stages, the results from these studies assessing the 
efficacy of cytokine-targeted therapies are promising and could be a key 
breakthrough in the treatment of SLE.  
 
Expert commentary  
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There has been major progress in the understanding of the intricate 
pathogenesis underlying SLE, most notably the critical role of auto B cells in 
autoantibody formation, antigen presentation and T cell activation. There are 
disadvantages with the current standard of care therapy and this has led to a 
pursuit for biologics that target specific SLE disease pathways.  
 
The approval of Belimumab by the FDA in 2011 was a significant milestone for 
the treatment of SLE. Furthermore murine models and early phase studies of 
epratuzumab and sifalimumab have shown promising results and multicentre 
randomised controlled trials with long-term follow-ups are ongoing.  
However, response to B cell target therapy is still heterogeneous among the 
studies. Understanding the B cell signalling pathways along with their lupus-
relevant molecular aberrations identified may allow for more targeted and 
rational interventions. More critically, this will explain the different rate of 
response showed when targeting different compounds of B cell populations.  
Taking into account the successful implementation of small molecule-mediated 
inhibition in haematologic malignancies, the idea of providing a specific, tailored 
to the patient’s ‘molecular identity’ and possibly less toxic therapeutic agent in 
patients with SLE appears fascinating. In order to avoid unnecessary effects on 
other cells, and not creating another unspecific immunosuppressant, it would be 
ideal to target molecules that are B cell specific. In light of this, Lyn and Btk 
modulation appears to be more rational (50). The study of small molecules that 
inhibit specific B cell signalling enzymes and mediators in lupus-prone animal 
models offers an important insight and also provides the background to attempt 
similar trials in humans. 
 
The actual body of evidence on safety issues of biologic therapies in SLE is 
limited for most drugs. The only exception is the use of B cell blockade with 
Rituximab (off-label) and anti-BLyS with Belimumab (approved).  
While the use of B cell depletion therapies as first-line treatment or in patients 
with a predominantly mild form of the disease is not recommended, their off-
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label use in severe, refractory SLE cases appears to be sufficiently positive to 
warrant their continued use in these patients. 
Although the results of these trials suggest that the use of Rituximab in SLE may 
be controversial, it is still used extensively ‘off label’. Further trials will need to 
prove more successful in order to establish Rituximab has an effective novel 
therapy for SLE; however this may prove to be difficult with the increasing 
emergence of biosimilars to the market (51).    
 
 
5-year view 
 
Agents that target B cells are not appropriate for all patients with SLE. Patients 
may have slightly different underlying pathophysiology rendering interventions 
ineffective in some patients but effective in others. Comparing the efficacy of 
various biologics in different patient subpopulations as well as in different SLE 
manifestations would help determine which biologics are most suited for certain 
types of patients and clinical manifestations. This would result in both clinically 
and cost effective novel biologics for SLE.  
 
The principle of treating-to-target has been successfully applied to many 
diseases outside rheumatology and more recently to rheumatoid arthritis. 
Identifying appropriate therapeutic targets and pursuing them systematically 
has led to improved care for patients with these diseases and useful guidance for 
healthcare practitioners and administrators. More recently, an initiative to 
evaluate possible therapeutic targets and develop treat-to-target guidance in the 
management of SLE was established. The therapeutic armamentarium for SLE 
consist of a relatively small number of agents in the therapeutic classes of 
glucocorticoids, anti-malarials, immunosuppressives and biologics. In the latter 
category, only one agent (Belimumab) is approved for use in SLE, and one 
(Rituximab) is used not infrequently ‘off-label’ in refractory cases. Fortunately, 
several new agents of considerable interest are in the development for the 
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treatment of SLE, raising expectations that will soon be possible to aim for 
therapeutic targets with greater confidence that they can be achieved (2).   
 
Key issues 
 Belimumab is the first drug licensed for use in SLE in more than fifty 
years. 
 Open label and uncontrolled studies supported the use of B cell depleting 
agents in refractory/life-threatening SLE, despite the poor outcome of 
two RTCs.   
 Careful evaluation of the risk/benefit profiles of biologic agents in SLE is 
essential.  
 Understanding the B cell signalling pathways along with their lupus-
relevant molecular aberrations identified may allow for more targeted 
and rational interventions  
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Figure legend  
Novel biologics and their respective targets in the pathogenesis of SLE. IL-1: 
Interleukin 1; IL-1 R: Interleukin 1 Receptor; IL-6: Interleukin 6; IL-6 R: 
Interleukin 6 Receptor; INFα: Interferon alpha; INFα R: Interferon alpha 
Receptor; CTLA4: Cytotoxic T Lymphocyte-associated antigen 4; BLyS: B 
Lymphocyte stimulator; APRIL: A Proliferation Inducing Ligand; BAFF-R: BLyS 
receptor; TACI: Transmembrane Activator and Calcium-modulator and 
Cyclophilin Ligand Interactor; BCMA: B Cell maturation antigen.  
 
 
 
